Propionyl-L-carnitine is efficacious in ulcerative colitis through its action on the immune function and microvasculature

Clinical and Translational Gastroenterology

Volumn 5, Issue , 2014, Pages

  Scioli, Maria Giovanna ^a   Stasi, Maria Antonietta ^b   Passeri, Daniela ^a   Doldo, Elena ^a   Costanza, Gaetana ^a   Camerini, Roberto ^b   Fociani, Paolo ^c   Arcuri, Gaetano ^a   Lombardo, Katia ^b   Pace, Silvia ^b   Borsini, Franco ^b   Orlandi, Augusto ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Sigma Tau SpA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CARNITINE; EMERIAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE; PLACEBO; PROPIONIC ACID; PROPIONYLCARNITINE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; 5 ACETAMIDOSALICYLIC ACID; LEVO AMINOCARNITINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; FATTY ACID OXIDATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTESTINE BIOPSY; INTESTINE MUCOSA; LEUKOCYTE ADHERENCE; LYMPHOCYTIC INFILTRATION; MALE; MICROVASCULAR ENDOTHELIAL DYSFUNCTION; MICROVASCULATURE; MULTICENTER STUDY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; ULCERATIVE COLITIS; ADJUVANT THERAPY; BIOACCUMULATION; CYTOKINE RELEASE; DRUG MECHANISM; IMMUNITY; INTESTINE BLOOD FLOW; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; TREATMENT DURATION;

EID: 84898838006     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2014.4     Document Type: Article

References (45)

1. Danese S, Fiocchi C. Ulcerative Colitis. N Engl J Med 2011; 365: 1713-1725.
2. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-1517.
3. MacDonald TT, Monteleone I, Fantini MC et al. Regulation of homeostasis and inflammation in the intestine. Gastroenterology 2011; 140: 1768-1775.
4. Binion DG, West GA, Volk EE et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998; 352: 1742-1746.
5. Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 1999; 34: 66-74.
6. Hatoum OA. The intestinal microvasculature as a therapeutic target in inflammatory bowel disease. Ann N Y Acad Sci 2006; 1072: 78-97.
7. Roediger WE. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet 1980; 2: 712-715.
8. Chapman MA, Grahn MF. Ileal and colonic epithelial metabolism in quiescent ulcerative colitis. Gut 1994; 35: 1152-1153.
9. Bremer J. Carnitine metabolism and function. Physiol Rev 1983; 63: 1420-1479.
10. Li P, Park C, Micheletti R et al. Myocyte performance during evolution of myocardial infarction in rats: effects of propionyl-L-carnitine. Am J Physiol 1995; 268: 1702-1713.
11. Vanella A, Russo A, Acquaviva R et al. L -propionyl-carnitine as superoxide scavenger, antioxidant, and DNA cleavage protector. Cell Biol Toxicol 2000; 16: 99-104.
12. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-1621.
13. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA 2006; 295: 547-553.
14. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004; 44: 248-252.
15. Stasi MA, Scioli MG, Arcuri G et al. Propionyl-L-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPHoxidase 4-mediated superoxide production. Arterioscler Thromb Vasc Biol 2010; 30: 426-435.
16. Loffredo L, Marcoccia A, Pignatelli P et al. Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. Eur Heart J 2007; 28: 608-612.
17. Bene J, Komlósi K, Havasi V et al. Changes of plasma fasting carnitine ester profile in patients with ulcerative colitis. World J Gastroenterol 2006; 12: 110-113.
18. Gasbarrini G, Mingrone G, Giancaterini A et al. Effects of propionyl-L-carnitine topical irrigation in distal ulcerative colitis: a preliminary report. Hepatogastroenterology 2003; 50: 1385-1389.
19. Mikhailova TL, Sishkova E, Poniewierka E et al. Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. Aliment Pharmacol Ther 2011; 34: 1088-1097.
20. Orlandi A, Marcellini M, Pesce D et al. Propionyl-L-carnitine reduces intimal hyperplasia after injury in normocholesterolemic rabbit carotid artery by modulating proliferation and caspase 3-dependent apoptosis of vascular smooth muscle cells. Atherosclerosis 2002; 160: 81-89.
21. Ferlosio A, Arcuri G, Doldo E et al. Age-related increase of stem marker expression influences vascular smooth muscle cell properties. Atherosclerosis 2012; 224: 51-57.
22. Campagnolo L, Costanza G, Francesconi A et al. Sortilin expression is essential for pronerve growth factor-induced apoptosis of rat vascular smooth muscle cells. PLoSOne 2014; 9: e84969.
23. Haraldsen G, Kvale D, Lien B et al. Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. J Immunol 1996; 156: 2558-2565.
24. Corda S, Laplace C, Vicaut E et al. Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-alpha is mediated by ceramide. Am J Respir Cell Mol Biol 2001; 24: 762-768.
25. Marino MW, Dunbar JD, Wu LW et al. Inhibition of tumor necrosis factor signal transduction in endothelial cells by dimethylaminopurine. J Biol Chem 1996; 271: 28624-28629.
26. Plevy SE, Targan SR. Future therapeutic approaches for inflammatory bowel diseases. Gastroenterology 2011; 140: 1838-1846.
27. Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007; 42: 16-25.
28. Lindsay JO, Ciesielski CJ, Scheinin T et al. Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut 2003; 52: 363-369.
29. van Deventer SJ, Wedel MK, Baker BF et al. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1415-1425.
30. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844.
31. Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2010; 16: 52-57.
32. Van Hinsbergh VW, Scheffer MA. Effect of propionyl-L-carnitine on human endothelial cells. Cardiovasc Drugs Ther 1991; 5: 97-105.
33. Calò LA, Pagnin E, Davis PA et al. Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol 2006; 107: 54-60.
34. Stein J, Ries J, Barrett KE. Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. Am J Physiol 1998; 274: G203-G209.
35. Orlandi A, Bennett M. Progenitor cell-derived smooth muscle cells in vascular disease. Biochem Pharmacol 2010; 79: 1706-1713.
36. Goossens V, Grooten J, De Vos K et al. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci USA 1995; 92: 8115-8119.
37. Lassègue B, San Martín A, Griendling KK et al. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res 2012; 110: 1364-1390.
38. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med 2011; 51: 1289-1301.
39. Santos CX, Tanaka LY, Wosniak J et al. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal 2009; 11: 2409-2427.
40. Ago T, Kitazono T, Ooboshi H et al. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 2004; 109: 227-233.
41. Chen YH, Lin SJ, Chen YL et al. Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules. Cardiovasc Hematol Disord Drug Targets 2006; 6: 279-304.
42. Ogawa H, Binion DG, Heidemann J et al. Mechanisms of MAdCAM-1 gene expression in human intestinal microvascular endothelial cells. Am J Physiol Cell Physiol 2005; 288: C272-C281.
43. Gunnett CA, Lund DD, McDowell AK et al. Mechanisms of inducible nitric oxide synthasemediated vascular dysfunction. Arterioscler Thromb Vasc Biol 2005; 25: 1617-1622.
44. McCafferty DM. Peroxynitrite and inflammatory bowel disease. Gut 2000; 46: 436-439.
45. Dijkstra G, Moshage H, van Dullemen HM et al. Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J Pathol 1998; 186: 416-421.